company background image
ZLD

Zelira TherapeuticsASX:ZLD Stock Report

Market Cap

AU$53.6m

7D

21.6%

1Y

-43.0%

Updated

20 Oct, 2021

Data

Company Financials
ZLD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ZLD Overview

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Zelira Therapeutics
Historical stock prices
Current Share PriceAU$0.045
52 Week HighAU$0.035
52 Week LowAU$0.14
Beta1.07
1 Month Change12.50%
3 Month Change-4.26%
1 Year Change-43.04%
3 Year Change-29.69%
5 Year Changen/a
Change since IPO95.65%

Recent News & Updates

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

ZLDAU PharmaceuticalsAU Market
7D21.6%0.7%1.5%
1Y-43.0%6.7%21.1%

Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: ZLD underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is ZLD's price volatile compared to industry and market?
ZLD volatility
ZLD Beta1.07
Industry Beta1.31
Market Beta1

Stable Share Price: ZLD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ZLD's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aOludare Odumosuhttps://www.zeliratx.com

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.

Zelira Therapeutics Fundamentals Summary

How do Zelira Therapeutics's earnings and revenue compare to its market cap?
ZLD fundamental statistics
Market CapAU$53.56m
Earnings (TTM)-AU$8.55m
Revenue (TTM)AU$663.32k

81.8x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZLD income statement (TTM)
RevenueAU$663.32k
Cost of RevenueAU$228.22k
Gross ProfitAU$435.09k
ExpensesAU$8.98m
Earnings-AU$8.55m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0072
Gross Margin65.59%
Net Profit Margin-1,288.84%
Debt/Equity Ratio0%

How did ZLD perform over the long term?

See historical performance and comparison

Valuation

Is Zelira Therapeutics undervalued compared to its fair value and its price relative to the market?

1.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZLD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZLD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZLD is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: ZLD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZLD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZLD is good value based on its PB Ratio (1.4x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is Zelira Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

66.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelira Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Zelira Therapeutics performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZLD is currently unprofitable.

Growing Profit Margin: ZLD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.

Accelerating Growth: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: ZLD has a negative Return on Equity (-22.6%), as it is currently unprofitable.


Financial Health

How is Zelira Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ZLD's short term assets (A$6.1M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: ZLD's short term assets (A$6.1M) exceed its long term liabilities (A$460.6K).


Debt to Equity History and Analysis

Debt Level: ZLD is debt free.

Reducing Debt: ZLD currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZLD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ZLD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.5% each year


Dividend

What is Zelira Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZLD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZLD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZLD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Oludare Odumosu

0.75

Tenure

AU$559,617

Compensation

Dr. Oludare Odumosu serves as Director of Zelira Therapeutics Limited (formerly Zelda Therapeutics Ltd) since December 02, 2019. He serves as the Managing Director & Global Chief Executive Officer of Zelir...


CEO Compensation Analysis

Compensation vs Market: Oludare's total compensation ($USD418.41K) is above average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Oludare's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ZLD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: ZLD's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Zelira Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Zelira Therapeutics Limited
  • Ticker: ZLD
  • Exchange: ASX
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$53.565m
  • Shares outstanding: 1.19b
  • Website: https://www.zeliratx.com

Location

  • Zelira Therapeutics Limited
  • 101 St Georges Terrace
  • Level 3
  • Perth
  • Western Australia
  • 6000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:34
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.